|
A Phase IIIb, Interventional, Multicentre, Multinational, Randomised, Open-label Trial to Compare the Efficacy and Safety of Ovarian Stimulation With GONAL-f® and Luveris® Starting on Day 1 vs. Day 6 in Women Between 36 and 42 Years of Age Undergoing Assisted Reproductive Technique (ART)
|
Terminated
|
Lutropin alfa
|
3b
|
EMR200061_506
|
KAUH-J
|
|
A Phase III, Randomized, doublE-blind, placebo-controlled trial to evaluate Immunogenicity and Safety of the Gam-COVID-Vac combined vector vaccine in prophylactic Treatment for SARS-СoV-2 infection in Saudi Arabia
|
Completed
|
Gam-COVID-Vac combined vector vaccine against the SARS-CoV-2-induced coronavirus infection.
|
3
|
RC20/497/R
|
King Abdulaziz Medical City NG (Riyadh)
|
|
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
|
Ongoing
|
DOCETAXEL Paclitaxel TAMOXIFEN Letrozole
|
3
|
S1007
|
KFSH & RC-R
|
|
"A Phase III, Open-label, Randomized Study To Evaluate The Efficacy And Safety of Adjuvant Alectinib Versus Adjuvant Platinum-based Chemotherapy in Patients with Completely Resected Stage Ib (Tumors≥4 Cm) To Stage IIIa Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer "
|
Completed
|
ALECTINIB
|
3
|
BO40336
|
KFSH&RC-R
|
|
A Phase III, Multicentre, International, Randomised, Parallel Group, Double Blind Cardiovascular Safety Study of BI 10773 (10 mg and 25 mg Administered Orally Once Daily) Compared to Usual Care in Type 2 Diabetes Mellitus Patients With Increased Cardiovascular Risk
|
Completed
|
BI 10773
|
3
|
1245.25
|
KFMC
|
|
A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared with Teriflunomide, in Participants with Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety.
|
Ongoing
|
Evobrutinib
|
3
|
MS200527ˍ0082
|
King Faisal Specialist Hospital and Research Center (Jeddah)
|
|
"A phase III, Multicenter, Randomized, Double-blind Study to Assess Efficacy and Safety of Two Doses of Crizanlizumab versus placebo, with or without Hydroxyurea/Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Vaso-Occlusive Crises (STAND)"
|
Ongoing
|
Crizanlizumab
|
3
|
CSEG101A2301
|
King Fahad Medical City (Riyadh)
|
|
A PHASE III, MULTICENTER, RANDOMISED, DOUBLEBLIND, PLACEBOCONTROLLED STUDY OF ATEZOLIZUMAB (ANTI−PDL1 ANTIBODY) IN COMBINATION WITH PACLITAXEL COMPARED WITH PLACEBO WITH PACLITAXEL FOR PATIENTS WITH PREVIOUSLY UNTREATED INOPERABLE LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER
|
Completed
|
ATEZOLIZUMAB / PACLITAXEL
|
3
|
MO39196
|
IMC (Closed), KFSH (Closed), KFMC (Closed)
|
|
A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Sitagliptin in Pediatric Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control
|
Ongoing
|
Sitagliptin
|
3
|
MK0431-083
|
NGHA-R
|
|
A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-0431A (A Fixed-Dose Combination Tablet of Sitagliptin and Metformin) in Pediatric Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Therapy (Alone or in Combination With Insulin)
|
Completed
|
MK-0431A (Sitagliptin / Metformin)
|
3
|
MK0431-170
|
NGHA-R
|
